RALEIGH — GeneVentiv Therapeutics, Inc., a gene therapy developer, announced a license agreement with the University of North Carolina at Chapel Hill for a patent-pending, gene therapy for hemophilia.

The gene therapy, GENV HEM, offers a cure for hemophilia patients with or without inhibitors.

The company plans to have the therapy in clinics by the middle of 2022.

“There are promising gene therapies in development for hemophilia patients without inhibitors, but patients with inhibitors were being left behind,” GeneVentiv Therapeutics CEO Damon Race said in the release.

“We’re changing that with a gene therapy for all hemophilia patients with or without inhibitors,” Race added.

The release is available here.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism